Company profile: iOnctura
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapies targeting immunosuppression in the tumor microenvironment to improve immune checkpoint therapies. Pipeline includes Roginolisib (IOA-244), a PI3Kδ inhibitor in Phase Ib/II for solid tumors and hematological malignancies; IOA-289, an autotaxin inhibitor in Phase Ib/II for pancreatic and other CAF-driven tumors; and preclinical IOA-359 (TGF-β) and IOA-237 (CD73 mAb).
Products and services
- IOA-289: Phase Ib/II autotaxin inhibitor targeting pancreatic cancer and other CAF-driven tumors, inhibiting cancer cell growth, stimulating immune cell infiltration, and reducing fibrosis
- IOA-359: Preclinical TGF-β pathway inhibitor for selected solid tumors, designed to overcome tumor aggressiveness, immune escape, and therapy resistance
- Roginolisib (IOA-244): Phase Ib/II PI3Kδ inhibitor for solid tumors and hematological malignancies, targeting immune-mediated resistance and indications with high intrinsic PI3Kδ expression
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to iOnctura
BioVex
HQ: United Kingdom
Website
- Description: Provider of biological treatments for cancer and infectious diseases, focused on development and commercialization. Its cancer program includes OncoVEXGM-CSF, an oncolytic vaccine/cancer-destroying virus that replicates and spreads within solid tumors, causing tumor destruction, and it advances biological treatments for the prevention of infectious disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVex company profile →
hC Bioscience
HQ: United States
Website
- Description: Provider of engineered tRNA-based protein editing platforms and therapeutics, including PTCX (Patch) to suppress nonsense mutations in mRNA and restore full-length protein, SWTX (Switch) to mark disease-causing proteins for destruction, and engineered tRNA therapies to correct multiple mutant proteins across various disease indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full hC Bioscience company profile →
Ayala Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage small molecule therapeutics, including gamma secretase inhibitors that block Notch-pathway activation. Pipeline includes AL101 in Phase 2 for recurrent/metastatic adenoid cystic carcinoma and AL102 in Phase 2/3 for desmoid tumors, with a planned Phase 2 in relapsed/refractory T-cell acute lymphoblastic leukemia. Conducts clinical trials to evaluate safety and efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ayala Pharmaceuticals company profile →
Cartesian Therapeutics
HQ: United States
Website
- Description: Provider of potent, safer cell therapy in and beyond oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cartesian Therapeutics company profile →
Armune Bioscience
HQ: United States
Website
- Description: Provider of molecular diagnostic and prognostic tests for prostate, lung and breast cancers, enabling physicians and patients to make more personalized treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Armune Bioscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for iOnctura
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to iOnctura
2.2 - Growth funds investing in similar companies to iOnctura
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for iOnctura
4.2 - Public trading comparable groups for iOnctura
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →